During Thursday’s Current trade, Shares of Cloud Peak Energy Inc. (NYSE:CLD), lost -6.52% to $3.22.
GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) declared initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’). The study involved 16,485 patients from 43 countries who had chronic obstructive pulmonary disease (COPD) with moderate airflow limitation (FEV1 50-70% predicted) and either a history or raised risk of cardiovascular disease (CVD).
For the primary endpoint of the study, the risk of dying on FF/VI 100/25mcg was 12.2% lower than on placebo* over the study period, which was not statistically noteworthy(p=0.137).
For the first of two secondary endpoints, FF/VI 100/25mcg reduced the rate of lung function decline (as measured by forced expiratory volume in one second, ‘FEV1’) by 8mL per year contrast with placebo (p=0.019). As the primary endpoint was not met, statistical significance cannot be inferred from this result. For the other secondary endpoint, the risk of experiencing an on-treatment cardiovascular (CV) event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack [TIA]) at any time was 7.4% lower in patients taking FF/VI 100/25mcg as compared to placebo which was not statistically noteworthy(p=0.475).
Theravance, Inc., a royalty administration company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnership agreement and the planned alliance agreement with Glaxo Group Limited (GSK).
Shares of Geron Corporation (NASDAQ:GERN), inclined 2.32% to $3.31, during its current trading session.
Geron Corporation (GERN) announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the company’s telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid malignancies, essential thrombocythemia (ET) and myelofibrosis (MF). The papers are available online in the September 3rd issue at www.NEJM.org.
“The data in the ET and MF study publications in The New England Journal of Medicine provide compelling evidence that use of a telomerase inhibitor, such as imetelstat, may result in ground-breaking changes in how we approach the future treatment of hematologic myeloid malignancies,” said John A. Scarlett, Geron’s President and Chief Executive Officer.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Accenture Plc (NYSE:ACN), during its Thursday’s current trading session gained 0.97% to $96.45.
Accenture (ACN) has been positioned as a leader in the IDC MarketScape Worldwide Professional Services Firms for “SAP Suite on HANA” in Oil and Gas Vendor Assessment.
The report assessed services firms’ offerings and capabilities in SAP® Business Suite powered by SAP HANA®, counting business consulting, technology consulting, systems integration, application outsourcing and hosted application administration. It also considered vendors’ experience in serving oil and gas customers, global service delivery capabilities and intellectual property developed for SAP Business Suite powered by SAP HANA.
The report noted that Accenture “exercises this global scope and scale in a close partnership with SAP and reports delivering more than 100 HANA projects, having more than 20 SAP credentials, concluding more than 80,000 hours of new SAP training as of mid-2014 and having more than 2,000 HANA implementation tools and accelerators in its repositories.”
Accenture plc provides administration consulting, technology, and business process outsourcing services worldwide. The company’s Communications, Media & Technology segment offers enterprise and industry-customized services in network engineering and integration, field force enablement, and IP network migration; provides online customer and enterprise relationship administration services; and assists customers in developing video-over-IP platforms, and transforming legacy broadcast platforms to digital.
Finally, Cloud Peak Energy Inc. (NYSE:CLD), decreased -6.38%, to $3.23.
Cloud Peak Energy Inc. (CLD), one of the largest U.S. coal producers and the only pure-play Powder River Basin (“PRB”) coal company, declared that Jim Orchard, Cloud Peak Energy’s Senior Vice President of Marketing, will speak at the Credit Suisse 28th Annual Basic Materials Conference at 2:30 p.m. ET on Thursday, September 17, 2015 in New York, New York.
Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The company operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments. It produces and sells sub-bituminous thermal coal with low sulfur content primarily to electric utilities operating in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
